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comprehensive review articles that describe the analytical 
issues, as well as the sensitivity and specificity, and other 
articles that present the performance of various biomark-
ers in various settings [4–6]. However, traditionally, heart 
failure was considered a disease characterised by contractile 
dysfunction and, as a result, most data on biomarkers were 
collected in patient cohorts with heart failure with reduced 
ejection fraction (HFrEF). Nowadays, we know that many 
patients suffer from heart failure with preserved ejection 
fraction (HFpEF), more related to a filling problem of the 
left ventricle but, importantly, also resulting in a pumping 
failure of the heart.
The aim of this overview is to describe several generally 
accepted and several novel biomarkers in HFpEF, focusing 
on the value these biomarkers have for diagnostic and prog-
nostic performance, and potential clinical utility.
Natriuretic peptides
The natriuretic peptides are by far the best studied and most 
widely accepted and employed biomarkers in heart failure, 
both in HFrEF and in HFpEF. The best studied natriuretic 
peptides are atrial natriuretic peptide and B-type natriuretic 
peptide (BNP). Mechanistically, transcription and release of 
both natriuretic peptides occurs in response to myocardial 
stretch [7, 8]. Besides BNP, clinicians can also measure NT-
pro B-type natriuretic peptide (NT-proBNP), which is the 
biologically inactive fragment that is formed after cleaving 
proBNP into the active hormone BNP (ratio 1:1) [7–9].
Nowadays, natriuretic peptides can easily be measured 
by fully automated and commercially available assays, 
which have proven excellent precision and reproducibility, 
also between laboratories. BNP and NT-proBNP correlate 
very well, but the clearance of NT-proBNP is exclusively 
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Abstract Biomarkers are widely used and studied in heart 
failure. Most studies have described the utility and perfor-
mance of biomarkers in sub-studies of randomised clinical 
trials, where the vast majority of the patients suffered from 
heart failure with reduced ejection fraction (HFrEF), and 
not with preserved ejection fraction (HFpEF). As a result, 
there is a scarcity of data describing the levels, dynamics, 
clinical and biochemical correlates, and biology of bio-
markers in patients suffering from HFpEF, whereas HFpEF 
is in fact a very frequent clinical entity. This article dis-
cusses the value of different biomarkers in HFpEF. We de-
scribe various aspects of natriuretic peptide measurements 
in HFpEF patients, with a focus on diagnosis, prognosis 
and the risk prediction of developing heart failure. Further, 
we will discuss several emerging biomarkers such as ga-
lectin-3 and suppression of tumorigenicity 2, and recently 
discovered ones such as growth differentiation factor-15 
and syndecan-1.
Keywords Heart failure · Preserved ejection fraction · 
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Introduction
In the last decades we have seen an explosion in numbers 
of new and emerging biomarkers, and the number of arti-
cles on this topic has steadily risen [1–3]. There are several 
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vide the clinician with a very good feel as to whether or not 
heart failure exists, and echocardiography will then lead to 
the diagnosis of heart failure, and can directly differentiate 
between HFpEF or HFrEF. The European Society of Car-
diology (ESC) guidelines on heart failure propose a cut-off 
of 125 pg/ml for NT-proBNP and 35 pg/ml for BNP in the 
above-described setting [15].
Tschöpe et al. conducted a study that provided evidence 
that natriuretic peptides may be used to diagnose HFpEF. 
Herein, the authors demonstrated that NT-proBNP lev-
els were strongly related to increased LV diastolic filling 
pressures, as determined by invasive measurements and 
end-diastolic wall stress in HFpEF patients [13]. The lat-
ter was confirmed by others [14], and NT-proBNP levels 
also appear to be related to tissue remodelling and fibrosis 
formation, which might also play a pivotal role in impaired 
relaxation. However, without exception these patients were 
‘pre-selected’, in the sense that they were referred because 
of a clinical suspicion of heart failure, and therefore had a 
high likelihood of having HFpEF, so that the cut-off points 
derived from these studies cannot be applied to all comers 
or asymptomatic subjects.
Identification of acute HFpEF patients
Clearly, acute heart failure patients present completely dif-
ferently than chronic stable heart failure patients. A crucial 
difference is that patients present acutely, usually to the 
emergency department, with symptoms of dyspnoea. Dur-
ing such episodes, the cardiac muscle endures high wall 
stress, which results in high values of natriuretic peptides in 
those with acute heart failure, regardless of a preserved or 
reduced ejection fraction. Maisel et al. showed that HFpEF 
patients who present with acute decompensated heart fail-
ure typically had BNP values of 600–1000 pg/ml [11]. Less 
severe HFpEF, in patients who were more compensated, 
resulted in lower BNP values (between 100 and 600 pg/ml) 
[16]. In a recent systematic review and meta-analysis that 
included 37 different study cohorts, the exclusionary cut-
point (for overall heart failure) of 100 pg/ml was confirmed 
for BNP and 300 pg/ml for NT-proBNP [17].
Prediction of new-onset HFpEF in the general 
population
Besides their diagnostic utility, natriuretic peptides might 
be used to identify subjects at risk of developing HFpEF 
over the course of many years, which is different from the 
diagnostic utility of natriuretic peptides. A possible utility 
for ‘signalling’ heart failure over a very long course has 
been shown for natriuretic peptides, and high-sensitivity 
troponin, for new-onset HFpEF in high-risk subjects from 
the general population [18], and the elderly [19]. Previ-
via the kidney whereas BNP is also cleared via the liver, 
resulting in different half-lives of the hormones.
Natriuretic peptides in HFpEF
Natriuretic peptides are moderately elevated in HFpEF 
patients [10–14], and levels may drop down to normal or 
near normal in symptom-free periods. This can be explained 
since natriuretic peptides are released and produced in 
response to increased myocardial wall stress. HFpEF is 
characterised by hypertrophic hearts with a small left ven-
tricular (LV) cavity, and this structural abnormality in itself 
does not elevate end-diastolic wall stress much, as can per-
fectly be concluded from Laplace’s law (Fig. 1). Under spe-
cific circumstances, such as supraventricular tachycardia or 
fluid overload, levels of natriuretic peptides may become 
very high (as in HFrEF), but this is uncommon. The lack 
of chronic elevations in wall stress comprehensively results 
in less natriuretic peptide production and lower circulating 
levels when compared with the levels in HFrEF. However, 
although the plasma levels of natriuretic peptides do not 
show extreme increases, it has been demonstrated that they 
gradually rise in parallel to the severity of diastolic abnor-
malities as assessed by e.g. echocardiography [10–14].
Identification of chronic stable HFpEF patients
There are no established cut-off points for HFpEF versus 
HFrEF, or versus heart failure as an entire group.
According to the heart failure guidelines [15] natriuretic 
peptides may be measured in the outpatient clinic to help 
stratify patients who are suspected for a diagnosis of heart 
failure (regardless of whether this HFpEF or HFrEF), and 
for whom it may be useful to order echocardiography. The 
primary goal is to distinguish between symptomatic (dys-
pnoeic) patients, who do or do not have heart failure. Exclu-
sionary cut-off points can be applied to this aim, because 
of very high negative predictive values (very low risk of 
false negatives). The combination of the medical history, 
signs and symptoms, and natriuretic peptide levels may pro-
Fig. 1 The law of Laplace
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be considered differently to the levels in HFpEF patients in 
sinus rhythm.
Besides atrial fibrillation, female sex and advanced age, 
both very common in HFpEF, are associated with elevated 
NT-proBNP [27]. In a study by McCullough et al. renal 
function was a confounder of BNP levels, especially in 
those with an eGFR less than 60 ml/min/1.73 m2. Finally, 
obesity is associated with lower BNP levels [28, 29], and 
lower cut-off values may be considered once the body mass 
index exceeds 35 kg/m2. Therefore clinicians who treat 
HFpEF patients and measure natriuretic peptide levels are 
advised to take the above-mentioned comorbidities into 
consideration when assessing the natriuretic peptide values.
Galectin-3 and suppression of tumorigenicity 2
Galectin-3 and suppression of tumorigenicity 2 (ST2) are 
emerging biomarkers that are not only predictive for hos-
pitalisation and death in patients with heart failure, but also 
add additional prognostic value over natriuretic peptides. As 
such, they received a class IIB recommendation by the 2013 
American College of Cardiology/American Heart Associa-
tion guideline for the management of heart failure for risk 
stratification [30].
Evidence has been generated specifically regarding the 
prognostic value of galectin-3 and ST2 in HFpEF patients, 
and patients with preclinical diastolic dysfunction.
Galectin-3
One of the first studies that compared galectin-3 levels 
between HFpEF and HFrEF patients was conducted by 
de Boer et al. [31]. The Coordinating study evaluating 
Outcomes of Advising and Counseling in Heart Failure 
(COACH) enrolled patients at discharge after being admit-
ted for acute heart failure, and 20 % (107 patients) were 
diagnosed with HFpEF (LVEF > 40 %). Interestingly, the 
authors found that galectin-3 appeared to have a particularly 
strong predictive value in HFpEF patients, compared with 
HFrEF patients. This finding highlighted the possibility of 
different pathophysiological mechanisms in the two sub-
types of heart failure.
Three additional HFpEF cohorts have since demonstrated 
the relation between galectin-3 and HFpEF.
First, Carrasco-Sánchez and colleagues demonstrated the 
predictive value of galectin-3 in 419 HFpEF patients (LVEF 
> 45 %) who were admitted with acute heart failure. Galec-
tin-3 independently predicted all-cause mortality and heart 
failure rehospitalisation, and yielded significant reclassifica-
tion indices [32]. Currently this study is one of the largest 
HFpEF biomarker studies that has been published.
ously, natriuretic peptides have been shown to be associated 
with preclinical diastolic dysfunction and the propensity 
to develop heart failure [20], although the performance of 
natriuretic peptides for the detection of subclinical diastolic 
dysfunction is not as good as for symptomatic diastolic dys-
function [21]. Therefore, natriuretic peptides alone lack the 
prognostic power to identify these patients, and it seems 
reasonable that a combination with clinical, electrocardio-
graphic, and biochemical risk factors may comprise a useful 
and powerful model for detecting those at risk for develop-
ing HFpEF in the community.
Plasma biomarkers: predicting prognosis in HFpEF
Epidemiological studies suggest that the overall prognosis is 
comparable for patients with HFpEF compared with HFrEF. 
However, in randomised controlled trials (RCTs), a certain 
bias exists because a ‘typical’ HFpEF patient usually has mul-
tiple comorbidities and often these comorbidities are exclu-
sion criteria for trials, and as a result patients suffering from 
them are excluded from such trials. Therefore, the patients 
with a high likelihood for an adverse event are paradoxi-
cally often excluded from HFpEF trials, and this results in 
a substantially lower cardiovascular risk in HFpEF patients 
enrolled in RCTs than in HFrEF patients enrolled in RCTs.
Nevertheless, the i-PRESERVE and the PEP-CHF stud-
ies demonstrated that both baseline values of NT-proBNP 
and change in NT-proBNP from baseline have prognostic 
value in patients with HFpEF, improving the prediction 
of mortality and heart failure rehospitalisation [22, 23]. 
When NT-proBNP increases from the baseline value, this 
was associated with an increased mortality and morbidity, 
while decreases in NT-proBNP levels were associated with 
reduced mortality and morbidity rates [22]. Van Veldhuisen 
et al. showed that despite the fact that natriuretic peptide 
levels are lower in HFpEF patients, compared with HFrEF 
patients, the predictive value of a given value of NT-proBNP 
is equal regardless of the ejection fraction [24].
Comorbidities common in HFpEF and their influence 
on natriuretic peptide levels
Atrial fibrillation is very common in HFpEF, and the pres-
ence of atrial fibrillation has a strong impact on circulating 
levels of natriuretic peptides. In patient cohorts with par-
oxysmal and chronic atrial fibrillation, natriuretic peptide 
levels are strongly elevated, often exceeding the values 
reported in HFpEF [25]. McKelvie et al. [26] even described 
a fivefold increase of natriuretic peptides compared with 
HFpEF patients with atrial fibrillation compared with 
HFpEF patients in sinus rhythm. Therefore, natriuretic pep-
tide levels in HFpEF patients with atrial fibrillation should 
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with HFpEF. These patients underwent echocardiography, 
biomarker assessment, and LV epicardial anterior wall 
biopsy. ST2 was higher in the hypertensive patients with-
out HFpEF compared with the control subjects. The ST2 
levels further increased in the hypertensive patients with 
HFpEF. Besides these increasing levels, ST2 was signifi-
cantly correlated with pulmonary capillary wedge pressure 
and increased collagen-dependent stiffness. These find-
ings support the hypothesis that ST2 is involved in HFpEF 
development and might play an early role in the induced 
pro-inflammatory pro-fibrotic state due to hypertension.
Other biomarkers in HFpEF
Besides natriuretic peptides, galectin-3 and ST2 several 
other biomarkers have been identified as potential mark-
ers for HFpEF. With respect to the biomarker levels, tissue 
inhibitor of metalloproteinases (TIMPs), aminoterminal 
propeptide of type III procollagen (PIIINP), homocysteine 
and resistin are particularly upregulated in HFpEF com-
pared with HFrEF. Whereas biomarkers of inflammation, 
such as pentraxin-3, C-reactive protein, tumour necrosis 
factor alpha (TNF-a), interleukin (IL)-6 and IL-10, show 
higher levels in HFrEF compared with HFpEF (Fig. 2).
Other markers of myocyte stress
Whereas NT-proBNP is the gold standard for myocyte 
stress, there are also other markers of cardiac loading that 
seem to have value in HFpEF. One of such factors is adre-
nomedullin, which is a hormone that is able to decrease 
systemic vascular resistance and also has diuretic and 
natriuretic effects. Levels of this hormone are elevated in 
patients with HFrEF, compared with healthy controls and 
identify patients with a restrictive filling pattern [41]. An 
additional diagnostic or prognostic value over NT-proBNP 
has not been demonstrated.
Other markers of extracellular matrix remodelling
Interstitial fibrosis is an important feature of heart failure 
with preserved ejection fraction, but myocyte stiffness plays 
an even more important role. This is reflected by the level of 
markers of extracellular matrix remodelling, such as matrix 
metalloproteinases (MMPs) 2 and 9, carboxy-terminal telo-
peptide of collagen type I (CITP) and PIIINP. All these bio-
markers are associated with outcome in HFpEF, although 
the independent predictive value of each marker was limited 
[42]. Syndecan-1 is a new marker of fibrosis and a member 
of the proteoglycan family. Its levels were correlated with 
other fibrotic biomarkers and were associated with clini-
cal outcome in HFpEF, but not in HFrEF. Syndecan-1 also 
Secondly, the ALDO-HF trial randomised HFpEF (LVEF 
≥ 50 %) patients to either a mineralocorticoid receptor 
antagonist (MRA, spironolactone) or placebo. Spironolac-
tone improved LV diastolic function, but did not affect max-
imal exercise capacity, patient symptoms, or quality of life 
[33]. Galectin-3 levels were measured at baseline, 6 months 
and 12 months and were only modestly elevated at baseline 
(median 12.1 ng/ml). Nevertheless galectin-3, and specifi-
cally increases in galectin-3, were independent of treatment 
and NT-proBNP associated with all-cause mortality or heart 
failure rehospitalisation [34].
The RELAX trial [35] was a multicentre, double-blind, 
placebo-controlled, parallel-group, randomised clinical trial 
of 216 stable outpatients with HFpEF (LVEF ≥ 50 %), eval-
uating the efficacy of sildenafil or placebo for 24 weeks. 
The authors showed in this third study that galectin-3 lev-
els were associated with age, smaller body size, and sever-
ity of renal dysfunction [36]. However, galectin-3 levels 
were not associated with comorbidities, symptomatic status 
or congestion, severity of LV remodelling or dysfunction, 
or exercise performance after adjusting for age, sex, and 
cystatin-C. It could be hypothesised that galectin-3, a bio-
marker associated with the remodelling process, may be less 
useful in patients with end-stage disease.
ST2
The first evidence that ST2 levels could be of interest in 
HFpEF patients was provided by a post-hoc analysis of 200 
HFpEF patients [37]. Although the study cohort consisted 
largely of African-Americans, ST2 was a better predictor 
for mortality than NT-proBNP. However, ST2 concentra-
tions did not correlate with echocardiographic indices of LV 
diastolic function.
More clinical data on ST2 in HFpEF was provided by 
Friões et al. [38]. The authors divided patients with acute 
heart failure based on LVEF, and reported that NT-proBNP 
predicted all-cause mortality or heart failure readmissions 
at 6 months regardless of LVEF. ST2 was reported to be 
a significant predictor of prognosis in HFrEF patients, but 
not in HFpEF patients. In contrast to the above-mentioned 
findings, data were reported of a pooled analysis including 
three cohorts from Boston, Massachusetts, Linz, Austria 
and Murcia, Spain. In 447 HFpEF patients admitted for 
acute heart failure, the authors demonstrated a comparable 
prognostic value of ST2 in both HFpEF and HFrEF [39].
Hypertension, a comorbidity that is most frequently 
present in HFpEF patients, might lead to different acti-
vated pathophysiological mechanisms in HFpEF. This 
was recently investigated by Zile et al. [40]. The authors 
measured ST2 in 70 coronary artery bypass graft patients 
stratified into three groups, control (no hypertension), hyper-
tensive patients without HFpEF and hypertensive patients 
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in the Health ABC study and was associated with incident 
HFpEF and to a lesser extent with HFrEF. The prognostic 
value is yet to be examined [49].
CA-125 is a tumour marker for ovarian cancer, but is also 
elevated in heart failure and is related to the severity of heart 
failure [50]. CA-125 levels increase when the heart failure 
stage or the level of diastolic dysfunction is more severe, 
although the levels of CA-125 were not different between 
patients with HFpEF and control patients [50].
vWF is an independent predictor of long-term outcome 
in patients with HFpEF, which may be explained by its 
role in endothelial dysfunction [51]. vWF was measured in 
457 patients of the Ludwigshafen Risk and Cardiovascu-
lar Health study and showed additional value beyond NT-
proBNP [51].
Conclusions
A large proportion of patients with heart failure suffer from 
HFpEF. In contrast to HFrEF, the role for biomarker assess-
ment in HFpEF has not been validated in full extent. No 
biomarker is specific for HFpEF; however, several mark-
ers have been shown to provide powerful and clinically 
meaningful information for the setting of the diagnosis and 
prognosis of HFpEF. As HFpEF is a very heterogeneous 
syndrome, likely not one but rather a panel of various bio-
markers, representing different aspects of the pathophysi-
ology, will provide the most powerful and sophisticated 
information for clinicians caring for patients with HFpEF. 
In the coming decades, such panels need to be identified, 
validated, and prospectively tested in the outpatient and 
inpatient setting.
showed improvement of risk stratification on top of clinical 
risk factors, including NT-proBNP [43].
Markers of inflammation
Inflammatory markers play an important role in the devel-
opment of heart failure. TNF-a and IL-6 were both associ-
ated with new-onset HFpEF, but less associated with HFrEF 
[44].
Other markers
Next to markers of myocyte stress, inflammation and extra-
cellular matrix remodelling, also other biomarkers are stud-
ied for their value in HFpEF. These biomarkers include 
growth differentiation factor-15 (GDF-15), cystatin C, 
resistin, cancer antigen-125 (CA-125) and von Willebrand 
factor (vWF).
GDF-15 is a member of the transforming growth factor 
(TGF)-beta family and correlates with cardiac hypertrophy 
and fibrosis. In 149 patients with LV diastolic dysfunction 
and normal ejection fraction, GDF-15 was found to be a 
potentially useful prognostic biomarker in patients with 
HFpEF, although the independent value was not assessed 
[45]. However, GDF-15 is not specific for HFpEF, it is 
also an independent predictor of mortality in patients with 
HFrEF [46].
Cystatin C is a marker of renal function that also pre-
dicts cardiovascular outcome. The serum cystatin C level 
in patients with HFpEF is an independent predictor for all-
cause mortality and/or readmission in patients with acute 
heart failure, regardless of renal function [47]. However, 
the prognostic value of cystatin C is lower in patients with 
HFpEF, compared with HFrEF patients [48].
Resistin is derived from adipose tissue and associated 
with inflammation. Resistin was measured in 2902 subjects 
KEY MESSAGE   Biomarkers important to distinguish between the normal situation and HFpEF
Fig. 2 Circulating biomarkers 
associated with pathophysiology 
of HFpEF. Since HFpEF is such 
a heterogeneous disease, it comes 
as no surprise that biomarkers 
which reflect various domains of 
the disease (myocardial structural 
remodelling and stretch, inflam-
mation, fibrosis, kidney function 
and more) are increased and may 
be used for the diagnosis and 
prognosis of HFpEF. Adapted 
from Mayo Foundation for Medi-
cal Education and Research
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